Neuland Laboratories Limited (NEULANDLAB)
Press Release
Press Release - Q2FY27
- Standalone revenue ₹457.2 Cr, down 11.4% y-y; EBITDA ₹104.6 Cr, margin 22.9% (-754 bps y-y); PAT ₹51.1 Cr, margin 11.2% (-751 bps y-y)
- Working capital days improved to 104 in H1FY27 from 155 in H1FY26
- New peptide manufacturing facility inaugurated with growing project pipeline
- Acquired 134 acres in Kakinada for long-term capacity expansion
- 2 DMFs filed for Fezolinetant and Ivacaftor in Q2FY27
- CEO: Growth expectations intact for FY27 and beyond; commercial CMS molecules driving near-term growth
- Earnings call scheduled for 2026-11-03 17:30 IST
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NEULANDLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NEULANDLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Neuland Laboratories Limited
Important.
The summary above is generated automatically from Neuland Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.